Positive trading and regulatory update
RUA Life Sciences’ trading update was accompanied by a regulatory update on its vascular graft products. Investors look for companies to do three things – achieve clinical, regulatory, and commercial success. While the first of these is awaiting all the clinical trial components to be in place, which the trading update notes that the company is now much closer to, we note RUA’s achievement of the second and third of these tasks.The valiant efforts that RUA has made on cost control and sales growth suggest that changes are needed to our revenue and YE 2023 cash estimates, but we are holding off making changes to our financials until the detail of RUA’s interim results expected on December 12th.
Our financial estimates and forecasts remain unchanged for the moment with Fair Value seen at £121.0m or 545p per share.
Aortech International is an Intellectual Property (IP) holding company whose principal activity is exploiting the value of its IP and know-how.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.